Sanara MedTech Inc. (NASDAQ:SMTI) Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC trimmed its position in shares of Sanara MedTech Inc. (NASDAQ:SMTI) by 41.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 32,846 shares of the company’s stock after selling 23,343 shares during the period. Janney Montgomery Scott LLC owned approximately 0.38% of Sanara MedTech worth $993,000 as of its most recent SEC filing.

Separately, Vanguard Group Inc. grew its stake in shares of Sanara MedTech by 3.1% during the first quarter. Vanguard Group Inc. now owns 144,394 shares of the company’s stock valued at $5,343,000 after acquiring an additional 4,348 shares in the last quarter. Institutional investors and hedge funds own 8.10% of the company’s stock.

Sanara MedTech Stock Performance

Shares of SMTI stock opened at $34.65 on Friday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.49 and a current ratio of 2.23. Sanara MedTech Inc. has a one year low of $26.00 and a one year high of $43.25. The company’s 50-day simple moving average is $32.43 and its 200-day simple moving average is $31.30. The stock has a market capitalization of $303.19 million, a price-to-earnings ratio of -35.35 and a beta of 1.55.

Sanara MedTech Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.